Johnson & Johnson's Kenvue files for IPO

• Kenvue CEO Thibaut Mongon said that the establishment of Kenvue is an important part of the spin -off restructuring plan, which can maximize the value of all stakeholders. In terms of positioning, KenVue competed with companies such as P & G and L'Oreal.
• Skin health/beauty sector revenue accounts for 30%, including 16 brands including Neutrogena, Ai Weinuo, Dr. Chengye, Oshuba, etc.; the revenue proportion of basic health sectors is 32%, including wound care, oral care, and oral care, and oral care, and oral care, and oral care, and oral care, and oral care. Baby care and women's health brands, including Li Shidelin, Chuangya Paste bandages and OB sanitary cotton bars, including 12 brands, including 38%of the revenue of personal care segments, including non -prescription medicines and health products, such as Tyno and Motalin and so on 16 brands.

 

Johnson & Johnson confirms launch of Kenvue IPO Roadshow; IPO expected to consist of 151.2 mln shares of common stock with an expected price range of $20-$23 per share 

• Co confirms that Kenvue Inc., a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering of 151,204,000 shares of its common stock.
• Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any.
• The IPO price is currently expected to be between $20.00 and $23.00 per share.
• Kenvue has applied to list its common stock on the New York Stock Exchange under the symbol "KVUE."
  
• After the completion of the IPO, JNJ will own 1,716,160,000 shares of Kenvue's common stock, representing 91.9% of the total outstanding shares of Kenvue's common stock (or 90.8% if the underwriters exercise in full their over-allotment option).
• Goldman Sachs (GS), J.P. Morgan (JPM) and BofA Securities (BAC) are acting as joint lead book-running managers for the IPO.